Next up on our fact or fiction series is one of the most common “rules” seen in the happy-dance-all-night-everyone-is-amazing world of MDMA (commonly known as Ecstasy or Molly). is whether taking selective serotonin reuptake inhibitors (SSRIs)—a common class of antidepressants—prevents it from working. Some claim that SSRIs completely block MDMA’s effects, while others believe they simply dull the experience. So, what’s the truth? Let’s break it down using science.
How MDMA Works in the Brain
MDMA’s signature effects—euphoria, emotional openness, and energy—are largely due to its massive release of serotonin, a neurotransmitter responsible for mood regulation and feelings of well-being (Cole & Sumnall, 2003)1. MDMA doesn’t just increase serotonin levels—it also prevents the brain from reabsorbing serotonin too quickly, allowing it to stay active longer in the brain (Green et al., 2003)2.
How SSRIs Affect MDMA
SSRIs, such as fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro), work by blocking the reuptake of serotonin, meaning they increase baseline serotonin levels over time. However, SSRIs also occupy the same transporter sites in the brain that MDMA needs to work (Hysek et al., 2012)3.
This prevents MDMA from triggering a massive serotonin release, leading to a much weaker or even nonexistent high. Some studies suggest that SSRIs can reduce MDMA’s effects by 80-90% (Liechti et al., 2000)4.
Does This Mean MDMA Is Completely Ineffective?
Not necessarily. While SSRIs block most of MDMA’s serotonin-related effects, some people still report experiencing mild stimulant effects. It may not be kicking the serotonin into overdrive, but MDMA still influences dopamine and norepinephrine. However, the euphoria and empathetic connection effects of MDMA (which are the highs that people are really looking for) are greatly reduced or absent.
The Dangers of Combining MDMA and SSRIs
Beyond just dulling the high, combining MDMA with SSRIs can be dangerous. Here’s why:
- Risk of Serotonin Syndrome – Although MDMA is less effective when taking SSRIs, there’s still a risk of serotonin syndrome, a potentially life-threatening condition where serotonin levels become dangerously high, leading to fever, seizures, and even organ failure (Boyer & Shannon, 2005)5.
- Worsening Depression and Anxiety – MDMA can cause a “crash” after the drug wears off, leaving those danced-out happy ravers feeling worse in the following days. This can be especially problematic for people with depression or anxiety disorders.
Final Verdict: (Mostly) True
SSRIs significantly reduce or eliminate the effects of MDMA because they block the serotonin transporter that MDMA relies on. While some stimulant effects may still occur, the classic euphoria and emotional openness associated with MDMA are largely absent.
Additionally, combining MDMA with SSRIs can pose serious health risks, including serotonin syndrome. If someone is on SSRIs for depression or anxiety, taking MDMA is not only ineffective but also potentially dangerous.
When in doubt, it’s always best to seek the truth by asking professionals like DanceSafe or a specialized substance abuse therapist!
Sources (I’m no librarian, but hopefully these are still accessible online):
- Cole, J. C., & Sumnall, H. R. (2003). The neurotoxicity of MDMA: A review of evidence and methodology. Neuropsychobiology, 47(1), 34-41. ↩︎
- Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pharmacological Reviews, 55(3), 463-508. ↩︎
- Hysek, C. M., Simmler, L. D., Nicola, V. G., Vischer, N., Donzelli, M., Krähenbühl, S., … & Liechti, M. E. (2012). Duloxetine inhibits effects of MDMA (Ecstasy) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One, 7(5), e36476. ↩︎
- Liechti, M. E., Baumann, C., Gamma, A., & Vollenweider, F. X. (2000). Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology, 22(5), 513-521. ↩︎
- Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. New England Journal of Medicine, 352(11), 1112-1120. ↩︎